The FDA has issued recent updates on several drugs that are currently in shortage or have been discontinued:
- Bupivacaine Hydrochloride and Epinephrine Injection, USP (Updated – Currently in Shortage)
- Bupivacaine Hydrochloride Injection, USP (Updated – Currently in Shortage)
- Calcium Gluconate Injection (Updated – Currently in Shortage)
- Diltiazem Hydrochloride ER (Twice-a-Day) Capsules (New – Currently in Shortage)
- Diphenhydramine Injection (Updated – Currently in Shortage)
- Eflornithine Hydrochloride (Vaniqa) Cream (Updated – Currently in Shortage)
- Hydromorphone Hydrochloride Injection, USP (Updated – Currently in Shortage)
- Leucovorin Calcium Lyophilized Powder for Injection (Updated – Currently in Shortage)
- Lidocaine Hydrochloride (Xylocaine) Injection (Updated – Currently in Shortage)
- Magnesium Sulfate Injection (Updated – Currently in Shortage)
- Methotrexate Sodium Injection (Updated – Currently in Shortage)
- Metoclopramide Injection, USP (Updated – Currently in Shortage)
- Morphine Sulfate Injection, USP (Updated – Currently in Shortage)
- Ondansetron Hydrochloride Injection (Updated – Currently in Shortage)
- Potassium Chloride Injection (Updated – Currently in Shortage)
- Potassium Phosphate Injection (Updated – Currently in Shortage)
- Progesterone Injection, USP (Updated – Currently in Shortage)
- Remifentanil (Ultiva) Lyophilized Powder for Solution Injection (Updated – Currently in Shortage)
- Ropivacaine Hydrochloride Injection (Updated – Currently in Shortage)
- Scopolamine Transdermal System (Updated – Currently in Shortage)
- Sodium Bicarbonate Injection, USP (Updated – Currently in Shortage)
- Sodium Chloride 23.4% Injection (Updated – Currently in Shortage)
- Sodium Chloride Injection USP, 0.9% Vials and Syringes (Updated – Currently in Shortage)
- Sodium Phosphate Injection (Updated – Currently in Shortage)
- Stavudine (Zerit) Powder for Oral Solution (New – Discontinuation)
- Sterile Water (Updated – Currently in Shortage)
According to the FDA:
“A drug receives Resolved status when the Drug Shortages Staff (DSS) determines that the market is covered, based on information from all manufacturers. The market is considered covered when supply is available from at least one manufacturer to cover total market demand. However, some manufacturers may not have all presentations available. DSS monitors the supply of products with Resolved status. For the most current supply information, contact the manufacturers.”
(Source: U.S. Food & Drug Adminstration)
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
